Sarilumab is a human monoclonal antibody against the interleukin-6 receptor.
Regeneron and Sanofi are currently co-developing the drug for the treatment of rheumatoid arthritis, for which it is in phase III trials. Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial.
On May 15th, 2013, both companies announced that 2 new trials were starting (COMPARE and ASCERTAIN) and the first patients had already been enrolled.
On November 22nd, 2013, both companies On May 15th, 2013, both companies announced positive phase 3 results for the RA-MOBILITY trial
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab". American Medical Association.
- ^ http://investor.regeneron.com/releasedetail.cfm?releaseid=590869
- ^ http://en.sanofi.com/Images/33027_20130515_sari_en.pdf